Global healthcare company Novo Nordisk on Friday launched a new semaglutide-based medication in the country, positioning it to help Filipinos with obesity or who are overweight manage their condition and address related comorbidities.
Called Wegovy, the drug contains semaglutide, a molecule that mimics the body’s natural hormone responsible for regulating appetite, GLP-1.
This helps users feel fuller, which may support weight reduction when combined with proper diet and physical activity.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
